[Peri- and postnatal study of cefodizime sodium in mice--intravenous administration from late gestation through period of lactation].
Peri- and postnatal study of cefodizime sodium (THR-221), a new developed cephem-type antibiotics, was carried out with ICR mice. THR-221 at dose levels of 0, 300, 1000 and 3000 mg/kg/day were administered intravenously to pregnant and delivered dams from day 15 of gestation through day 21 of lactation. No changes in body weights of dams in all treated groups but slight decrease in food consumptions of 3000 mg/kg/day group were observed. Treated sites, tails of a few dams in this group, were affected with inflammatory lesions because of repeated dosing. Neonates from dams treated with 3000 mg/kg/day were slightly decreased in body weight at birth. At term sacrifice of F 1 of 10 weeks age, absolute and relative spleen weights were decreased in male 3000 mg/kg/day group and in female 1000 and 3000 mg/kg/day group. No effects on other physical, behavioral or reproductive ability examinations of F 1 offspring were showed. It is suggested that no effect dose level of THR-221 is 1000 mg/kg/day and that of F 1 offspring is 300 mg/kg/day.
Yamakita
O
O
Drug Safety Laboratory, Taiho Pharmaceutical Co., Ltd., Tokushima-shi.
Koida
M
M
Shinomiya
M
M
Katayama
S
S
Ikebuchi
K
K
Ohuchida
A
A
Kouchi
Y
Y
Yoshida
R
R
D000818:Animals; D000831:Animals, Newborn / Q000254:growth & development*; D002439:Cefotaxime / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000633:toxicity; D005260:Female; D005333:Fetus / Q000187:drug effects*; D007275:Injections, Intravenous; D007774:Lactation; D008297:Male; D051379:Mice; D008813:Mice, Inbred ICR; D009929:Organ Size / Q000187:drug effects; D011247:Pregnancy; D013154:Spleen / Q000187:drug effects / Q000254:growth & development; D013997:Time Factors
D002439:Cefotaxime; C033356:cefodizime